Covid-19 roundup: Catalent lends vaccine production capacity to AstraZeneca/Oxford for hundreds of millions doses
Catalent’s growth play in Italy a year ago is paying off amid a dramatic explosion in demand for space to produce Covid-19 vaccines. In a new deal with AstraZeneca, the Anagni site is charged with filling the vials and packaging Oxford’s adenovirus vector-based candidate, now named AZD1222.
The supply could reach hundreds of millions of doses with round-the-clock manufacturing schedules, beginning as early as this August should regulators stamp their OK and through to March 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
